- Home
- THCH vs ATOS Comparison
THCH vs ATOS Comparison
Compare THCH & ATOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- THCH
- ATOS
- Stock Information
- Founded
- THCH 2018
- ATOS 2009
- Country
- THCH China
- ATOS United States
- Employees
- THCH N/A
- ATOS N/A
- Industry
- THCH Blank Checks
- ATOS Biotechnology: Pharmaceutical Preparations
- Sector
- THCH Finance
- ATOS Health Care
- Exchange
- THCH Nasdaq
- ATOS Nasdaq
- Market Cap
- THCH 141.1M
- ATOS 114.5M
- IPO Year
- THCH N/A
- ATOS 2012
- Fundamental
- Price
- THCH $3.10
- ATOS $0.80
- Analyst Decision
- THCH
- ATOS Strong Buy
- Analyst Count
- THCH 0
- ATOS 3
- Target Price
- THCH N/A
- ATOS $7.00
- AVG Volume (30 Days)
- THCH 21.0K
- ATOS 678.1K
- Earning Date
- THCH 04-17-2025
- ATOS 03-31-2025
- Dividend Yield
- THCH N/A
- ATOS N/A
- EPS Growth
- THCH N/A
- ATOS N/A
- EPS
- THCH N/A
- ATOS N/A
- Revenue
- THCH $207,029,179.00
- ATOS N/A
- Revenue This Year
- THCH N/A
- ATOS N/A
- Revenue Next Year
- THCH N/A
- ATOS N/A
- P/E Ratio
- THCH N/A
- ATOS N/A
- Revenue Growth
- THCH N/A
- ATOS N/A
- 52 Week Low
- THCH $2.78
- ATOS $0.72
- 52 Week High
- THCH $7.20
- ATOS $2.31
- Technical
- Relative Strength Index (RSI)
- THCH 47.40
- ATOS 41.00
- Support Level
- THCH $2.97
- ATOS $0.79
- Resistance Level
- THCH $3.24
- ATOS $0.89
- Average True Range (ATR)
- THCH 0.21
- ATOS 0.05
- MACD
- THCH 0.02
- ATOS 0.01
- Stochastic Oscillator
- THCH 21.64
- ATOS 25.14
About THCH TH International Limited Ordinary shares
TH International Ltd is the parent company of the franchise of Tim Hortons coffee shops and has the rights to operate Tim Hortons coffee shops in mainland China, Hong Kong, and Macau. Through the Tim Hortons brand, the firm offers freshly brewed coffee, tea, and other beverages, bakery & sides, and sandwiches. It is also the operator and developer of Popeyes brand in Mainland China. The firm has two reportable segments; Tim Hortons which generates key revenue, and Popeyes. The company's revenue is derived from its operations in the PRC.
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary innovative medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.